, Volume 70, Issue 5, pp 541–559 | Cite as

Nomegestrol Acetate

Pharmacology, Safety Profile and Therapeutic Efficacy
Review Article


This review summarizes the pharmacology, safety and clinical efficacy of nomegestrol acetate, based on the available published literature, and assesses the pharmacological characteristics that underlie a role in different gynaecological disorders and hormone replacement therapy (HRT), and a potential role in combination estrogen/progestogen oral contraception. Nomegestrol acetate is a potent, orally active progestogen with a favourable tolerability profile and neutral metabolic characteristics. Unlike the majority of older progestogens, which were 19-nortestosterone derivatives synthesized primarily for their antigonadotropic activity as a component of hormonal contraception in combination with an estrogen, nomegestrol acetate is a 19-norprogesterone derivative designed to bind specifically to the progesterone receptor, and is relatively lacking in affinity for other steroid receptors. Nomegestrol acetate exerts strong antiestrogenic effects at the level of the endometrium and has potent antigonadotropic activity, but without any residual androgenic or glucocorticoid properties. At a dosage of 1.25 mg/day, nomegestrol acetate inhibits ovulation while permitting follicle growth, whereas at dosages of 2.5 or 5 mg/day, both ovulation and follicle development are suppressed. The antigonadotropic action of nomegestrol acetate is mediated, like other progestins, at the hypothalamic and pituitary level. Moreover, nomegestrol acetate has partial antiandrogenic activity. Absorption of nomegestrol acetate is rapid after oral administration, reaching a peak serum concentration within 4 hours, with a terminal half-life of approximately 50 hours.

Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of HRT in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. In vitro data suggest that nomegestrol acetate preserves the beneficial haemostatic effects of estrogen; furthermore, nomegestrol acetate has a neutral or beneficial effect on lipid profiles, and does not adversely affect glucose metabolism or bodyweight. Nomegestrol acetate has shown a lack of profilerative activity in normal and cancerous breast tissue, and does not have a deleterious effect on bone remodelling.

These potent antigonadotropic properties, and other beneficial metabolic and pharmacological characteristics, suggest that nomegestrol acetate can be an effective progestogen for use in combination with an estrogen in oral estrogen/progestogen contraceptive treatment and in HRT, while it also provides some non-contraceptive benefits for women’s health.


  1. 1.
    Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996 Feb; 51(2): 188–215PubMedCrossRefGoogle Scholar
  2. 2.
    Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21(13): 865–83PubMedCrossRefGoogle Scholar
  3. 3.
    Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003 Dec 10; 46 Suppl. 1: S7–16PubMedCrossRefGoogle Scholar
  4. 4.
    Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004 Apr 15; 47(4): 277–83PubMedCrossRefGoogle Scholar
  5. 5.
    Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006 Mar–Apr; 12(2): 169–78PubMedCrossRefGoogle Scholar
  6. 6.
    Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol 2007 Oct; 23 Suppl. 1: 32–41PubMedCrossRefGoogle Scholar
  7. 7.
    Kumar N, Koide SS, Tsong Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000 Oct–Nov; 65(10–11): 629–36PubMedCrossRefGoogle Scholar
  8. 8.
    Paris J, Thevenot R, Bonnet P, et al. The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. Arzneimittelforschung 1983; 33(5): 710–5PubMedGoogle Scholar
  9. 9.
    Duc I, Botella J, Bonnet P, et al. Antiandrogenic properties of nomegestrol acetate. Arzneimittelforschung 1995 Jan; 45(1): 70–4PubMedGoogle Scholar
  10. 10.
    Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann N Y Acad Sci 1977 Mar 11; 286: 321–30PubMedCrossRefGoogle Scholar
  11. 11.
    Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol 1987 Dec; 94(12): 1199–204PubMedCrossRefGoogle Scholar
  12. 12.
    Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 1999 Nov; 84(11): 4191–6PubMedCrossRefGoogle Scholar
  13. 13.
    Couzinet B, Young J, Brailly S, et al. The antigonadotropic activity of progestins (19-nortestosterone and 19-norpro-gesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab 1996 Dec; 81(12): 4218–23PubMedCrossRefGoogle Scholar
  14. 14.
    Data on file, Theramex S.p.A., 2002Google Scholar
  15. 15.
    Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993 Oct; 46(4): 507–14PubMedCrossRefGoogle Scholar
  16. 16.
    Dusterberg B, Humpel M, Speck U. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. Contraception 1981 Dec; 24(6): 673–83PubMedCrossRefGoogle Scholar
  17. 17.
    Cohen A. Multicenter study of the clinical use of nomegestrol acetate in outpatients. Contracept Fertil Sex (Paris) 1994; 21: 417–27Google Scholar
  18. 18.
    Cohen A, Engelmann P, Erny R, et al. Lutenyl and menstrual disorders: a hospital study. Rev Fr Gynecol Obstet 1988 Nov; 83(11): 741–3PubMedGoogle Scholar
  19. 19.
    Persiani P, Radici E, Lombardi PA, et al. Use of nomegestrol acetate in the treatment of menstruation disorders: our experience in 56 cases. Minerva Ginecol 1997 Apr; 49(4): 181–5PubMedGoogle Scholar
  20. 20.
    Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995 Nov; 64(5): 957–62PubMedGoogle Scholar
  21. 21.
    Fraser DI, Padwick ML, Whitehead MI, et al. The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas 1989 Mar; 11(1): 21–34PubMedCrossRefGoogle Scholar
  22. 22.
    De Leo V, la Marca A, Morgante G, et al. Comparison of two HRT regimens with bimonthly and monthly progestin administration in postmenopause. Maturitas 1999 Jan 4; 31(2): 171–7PubMedCrossRefGoogle Scholar
  23. 23.
    Di Carlo C, Sammartino A, Di Spiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005 Sep–Oct; 12(5): 520–5PubMedCrossRefGoogle Scholar
  24. 24.
    Chretien FC, Dubois R. Effect of nomegestrol acetate on spinability, ferning and mesh dimension of midcycle cervical mucus. Contraception 1991 Jan; 43(1): 55–65PubMedCrossRefGoogle Scholar
  25. 25.
    Coutinho EM. One year contraception with a single sub-dermal implant containing nomegestrol acetate (Uniplant). Contraception 1993 Jan; 47(1): 97–105PubMedCrossRefGoogle Scholar
  26. 26.
    Devoto L, Kohen P, Barnhart K, et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum Reprod 1997 Apr; 12(4): 708–13PubMedCrossRefGoogle Scholar
  27. 27.
    Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991 Dec; 44(6): 599–605PubMedCrossRefGoogle Scholar
  28. 28.
    Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996 Oct 12; 348(9033): 977–80PubMedCrossRefGoogle Scholar
  29. 29.
    Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996 Oct 12; 348(9033): 981–3PubMedCrossRefGoogle Scholar
  30. 30.
    Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997 Mar 15; 314(7083): 796–800PubMedCrossRefGoogle Scholar
  31. 31.
    Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001 Jul; 86(1): 112–23PubMedGoogle Scholar
  32. 32.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346(8990): 1593–6PubMedCrossRefGoogle Scholar
  33. 33.
    Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000 Nov 11; 321(7270): 1190–5PubMedCrossRefGoogle Scholar
  34. 34.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 Dec 16; 346(8990): 1582–8Google Scholar
  35. 35.
    Zerr-Fouineau M, Chataigneau M, Blot C, et al. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 2007 Jan; 21(1): 265–73PubMedCrossRefGoogle Scholar
  36. 36.
    Zerr-Fouineau M, Jourdain M, Boesch C, et al. Certain progestins prevent the enhancing effect of 17s betas -estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29(4): 586–93PubMedCrossRefGoogle Scholar
  37. 37.
    Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 Aug 9; 362(9382): 428–32PubMedCrossRefGoogle Scholar
  38. 38.
    Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007 Feb 20; 115(7): 840–5PubMedCrossRefGoogle Scholar
  39. 39.
    Canonico M, Oger E, Plu-Bureau G, et al. Response to letter regarding article, “Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study” [letter]. Circulation 2007; 116: e363CrossRefGoogle Scholar
  40. 40.
    Post MS, Hendriks DF, Van Der Mooren MJ, et al. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women. J Intern Med 2002 Mar; 251(3): 245–51PubMedCrossRefGoogle Scholar
  41. 41.
    van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000 Jan; 83(1): 29–34PubMedGoogle Scholar
  42. 42.
    Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001 Jul–Aug; 8(4): 245–51PubMedCrossRefGoogle Scholar
  43. 43.
    Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995 Feb; 85(2): 304–13PubMedCrossRefGoogle Scholar
  44. 44.
    Toni F, Lentini GM, Baldi S, et al. Endometrial histopathology and compliance of the treatment with nomegestrolo acetate versus micronized vaginal progesterone in the transdermal estrogen replacement therapy [abstract]. 2nd International Symposium on Women’s Health and Menopause; 1996 Dec 4–7; FlorenceGoogle Scholar
  45. 45.
    Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994 Dec; 24(7): 1757–61PubMedCrossRefGoogle Scholar
  46. 46.
    Williams JK, Cline JM, Honore EK, et al. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998 Nov; 179(5): 1288–94PubMedCrossRefGoogle Scholar
  47. 47.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33PubMedCrossRefGoogle Scholar
  48. 48.
    Chakhtoura Z, Canonico M, Gompel A, et al. Progestogenonly contraceptives and the risk of stroke: a meta-analysis. Stroke 2009; 40(4): 1059–62PubMedCrossRefGoogle Scholar
  49. 49.
    Gerich JE. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clin Cornerstone 2007; 8(3): 53–68PubMedCrossRefGoogle Scholar
  50. 50.
    The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995 Jan 18; 273(3): 199–208CrossRefGoogle Scholar
  51. 51.
    Dorangeon P, Thomas JL, Gillery P, et al. Short term effects on lipids and lipoproteins of two progesterones used in postmenopausal replacement therapy. Eur J Clin Res 1992; 3: 187–93Google Scholar
  52. 52.
    Dorangeon P, Thomas JL, Choisy H, et al. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab 1993 Sep-Oct; 19(5): 441–5PubMedGoogle Scholar
  53. 53.
    Gol M, Akan P, Dogan E, et al. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006 Feb 20; 53(3): 252–9PubMedCrossRefGoogle Scholar
  54. 54.
    Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 Aug 9; 362(9382): 419–27PubMedCrossRefGoogle Scholar
  55. 55.
    Speroff L. The Million Women Study and breast cancer. Maturitas 2003 Sep 25; 46(1): 1–6PubMedCrossRefGoogle Scholar
  56. 56.
    Shields-Botella J, Chetrite G, Meschi S, et al. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol 2005 Jan; 93(1): 1–13PubMedCrossRefGoogle Scholar
  57. 57.
    Chetrite G, Paris J, Botella J, et al. Effect of nomegestrol acetate on estrone-sulfatase and 17beta-hydroxysteroid dehydrogenase activities in human breast cancer cells. J Steroid Biochem Mol Biol 1996 Aug; 58(5–6): 525–31PubMedCrossRefGoogle Scholar
  58. 58.
    Chetrite GS, Thomas JL, Shields-Botella J, et al. Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues. Anticancer Res 2005 Jul–Aug; 25(4): 2827–30PubMedGoogle Scholar
  59. 59.
    Chetrite GS, Paris J, Shields-Botella J, et al. Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines. Anticancer Res 2003 Nov–Dec; 23(6C): 4651–5PubMedGoogle Scholar
  60. 60.
    Botella J, Duranti E, Duc I, et al. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994 Jul; 50(1–2): 41–7PubMedCrossRefGoogle Scholar
  61. 61.
    Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993 May; 67(5): 945–52PubMedCrossRefGoogle Scholar
  62. 62.
    Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995 Nov; 55(2): 239–46PubMedCrossRefGoogle Scholar
  63. 63.
    Nguyen-Pascal ML, Thomas JL, Bergougnoux L, et al. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period. Climacteric 2005 Jun; 8(2): 136–45PubMedCrossRefGoogle Scholar
  64. 64.
    Cohen A, Denis C, Thomas JL. Treatment of perimenopausal women with 5 mg/d of nomegestrol acetate for 20 days of the cycle. Contracept Fertil Sex (Paris) 1992; 20(11): 1054–7Google Scholar
  65. 65.
    Medical News Today. Pivotal phase IIIa trials for Organon’s novel oral contraceptive, NOMAC/E2: complete recruitment [online]. Available from URL: http://www.medicalnewstoday.com/articles/71276.php [Accessed 2010 Jan 14]
  66. 66.
    Schering-Plough. Efficacy and safety study of the combined oral contraceptive NOMAC-E2 compared to a COC containing DRSP/EE (292002) [COMPLETED] (P05722) [ClinicalTrials.gov identifier NCT00413062]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 5]
  67. 67.
    Schering-Plough. Effects on ovarian function of the combined oral contraceptive NOMAC-E2 compared to a COC containing DRSP/EE (292003) [COMPLETED] (P05723) [ClinicalTrials.gov identifier NCT00511433]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 5]

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Endocrinological Gynecology, Pathophysiology of Menopause and Osteoporosis UnitIRCCS-Istituto Dermopatico dell'ImmacolataRomeItaly

Personalised recommendations